|66.29|| +0.23 / +0.35%|
Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. The company operates its business through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment produces and markets branded pharmaceuticals and biopharmaceuticals, specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems and radiopharmaceuticals. Mallinckrodt was founded on January 9, 2013 and is headquartered in Dublin, Ireland.
|Mark C. Trudeau||President, Chief Executive Officer & Director|
|Frank Scholz||Senior Vice President-Global Operations|
|Matthew K. Harbaugh||Chief Financial Officer & Senior Vice President|
|Steven Romano||Chief Scientific Officer & Senior Vice President|
|Sandra L. Hatten||Senior VP-Quality & Regulatory Compliance|